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Background: At fluorodeoxyglucose/positron emission tomography (FDG/PET) examinations, a generally increased
uptake of the skeletal muscles is sometimes encountered. As the tracer distribution constitutes a ‘zero-sum-game’,
the uptake of lesions as well as of normal tissues is reduced in these patients. This has to be considered at calculation
of standardised uptake values (SUVs), especially at longitudinal examinations in the same patient. In the current study,
a possible similar influence on the FDG distribution by a high uptake of brown adipose tissue (BAT) was studied.
Methods: Twelve patients with strongly increased BAT uptake were examined twice with a mean of 5 days (study group).
In six of these patients, there was at least one pathological lesion with increased uptake. The BAT uptake was normalised
at the second examination after pretreatment with propranolol. SUVs of the pathological lesions and of the liver, spleen,
lung, blood, skeletal muscles, bone marrow, gluteal fat, abdomen and heart were assessed. In order to control the effects
of propranolol on normal organs/tissues, which could interfere with the findings, 25 age and gender matched normal
controls were also studied (control subjects).
Results: In the study group, there was only a lower bone marrow uptake after propranolol administration. Comparing the
study group with the control subjects, the bone marrow activity was higher at examination before propranolol treatment
compared to the control subjects. There was also a higher uptake of the spleen in the study group before propranolol
treatment compared to the control subjects. There were no differences between the study group after propranolol
administration and the control subjects.
Conclusions: The differences found are small and cannot be explained, why they could be random phenomena.
Together with, there were no differences between the study group after propranolol administration and the control
subjects; it is concluded that an effect on the FDG distribution in patients with a strong BAT uptake by can be
disregarded in clinical praxis. This is important at longitudinal examinations of patients undergoing tailored tumour
therapy and in contrast to examinations in patients with a generally increased uptake of the skeletal muscles which
significantly affects the distribution of the radiopharmaceutical.
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We have previously reported that the distribution of
fluorodeoxyglucose (FDG) at positron emission tomog-
raphy (PET)-examinations more or less constitutes a
‘zero-sum-game’ [1]. This was studied by comparing the
tracer distribution in patients showing a high uptake of
the skeletal muscles with the tracer distribution at repeat
examination made a few days later after normalising the
muscular uptake. This was achieved after instructing the* Correspondence: henry.lindholm@karolinska.se
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in any medium, provided the original work is ppatient to refrain from physical activity, together with
diazepam pretreatment. Both the uptake of pathological
lesions and of various normal tissues significantly
increased after normalising the muscular activity. This
fundamental mechanism has previously been little studied.
Obviously, it has to be considered as it may influence the
interpretation of single standardised uptake values (SUVs)
as well as of longitudinal examinations in the same patient
at therapy assessments.
Another phenomenon that could affect the FDG distri-
bution in the same way and disguise a relevant SUV is a
high uptake by brown adipose tissue (BAT) whichis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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studied in the current investigation which was performed
in the same way as in our previous study [1]. Patients with
a high BAT uptake, and being soon re-examined on clinical
grounds after normalisation of the uptake by treatment of
propranolol (β-blocker) prior to the tracer administration,
were assessed in retrospect. Propranolol effectively reduces
the FDG uptake of BAT [4,5]. In 12 consecutive such
patients, SUVs of various normal tissues were compared
between the two examinations. In order to control the
effects of propranolol on normal organs/tissues, 25 age and




Both included patient groups were evaluated in retrospect.
The study group constituted all patients with a strongly in-
creased BAT uptake of FDG being re-examined on clinical
grounds during the last 5 years after pretreatment with
propranolol at which the BAT uptake was normalised.
There were 12 patients (11 women and 1 man; mean age
35 ± 12 years). All patients were examined because of a
known or suspected malignancy, in six patients this being
malignant lymphoma. Six patients showed a normal find-
ing at the examination. In the remaining individuals, one
showed a single lesion with increased uptake, one individ-
ual showed two pathological lesions and in four individ-
uals there were ≥ 3 lesions. Propranolol (40 to 80 mg) was
administered orally 1 to 1.5 h prior to the administration
of FDG at the recall examinations. There was a mean of
5 ± 3 days between the two examinations. At the first
examination there was a mean of 72 ± 10 min between
tracer administration and examination. At the second
study there was a mean of 68 ± 10 min until examination.
The blood glucose level was available at both examina-
tions in 10 patients. At the first examination, the mean
value was 5.7 ± 0.5 mmole/l. At the second examination
this was 5.3 ± 0.5 mmole/l.
The control subjects were taken from our previously col-
lected 500 clinical patients with a normal, or near normal
FDG distribution [6]. It was not possible to establish con-
trols paired with regard to age and gender of the study
group. Instead, subjects forming a group with a similar
gender and age distribution as the study group were
consecutively picked out while going over our register.
Twenty-five individuals (3 men and 22 women) with a
normal blood glucose level (mean 5.1 ± 0.6 mmole/l) were
included. The mean age was 35 ± 12 years. There was a
mean of 59 ± 5 min between tracer administration and
examination. The study was approved by the Regional eth-
ics research committee (Regionala etikprövningsnämnden
i Stockholm, Karolinska Institutet, SE-171 77 Stockholm,
Sweden).PET/CT examination
B-glucose was measured immediately prior to adminis-
tration of FDG using the same glucometer, HemoCue®
Glucose 201+ (Hemocue AB, Ängelholm, Sweden). A
Biograph 64 TruePoint TrueV PET/computer tomography
(CT) scanner (Siemens Medical Solutions, Erlangen,
Germany) was used. FDG (4 MBq/kg bw) was administered
i.v. The scan usually included the mid-skull to the proximal
thigh. Prior to examination with contrast medium, a low-
dose CT was performed for attenuation and photon scatter
correction. Directly thereafter, the PET examination was
done, followed by a diagnostic (full-current) CT with or
without contrast medium. At examinations without con-
trast medium, the full-dose CT was used for attenuation
and scatter correction. The diagnostic CT examinations
were performed with a tube tension of 120 kV, a pitch of
0.8, a slice thickness of 1.2 mm and a rotation speed of
0.5 s. The current was set to 160 mAs (reference), and dose
modulation (CARE Dose4D) was applied. In the examina-
tions done only for photon attenuation and scattering cor-
rection, CT was performed with a tube tension of 120 kV, a
pitch of 0.8, a slice thickness of 1.2 mm, a rotation speed of
0.5 s and a current of 50 mAs. CT acquisitions were always
done with the breath-holding technique at a mean in-
spiratory level. 3D PET acquisition was done for 3 min
at each bed position during normal tidal breathing. The
PET data were subsequently reconstructed with the
manufacturer’s 2D-OSEM algorithm (four iterations
and eight subsets) using a 5-mm Gaussian post-recon
struction filter. The image matrix size was 168 × 168 with
a slice thickness of 5 mm. In addition to attenuation and
scatter correction, all data were corrected for dead time
and random coincidences.
Image analysis
Activity quantification was done in the PET images using
Siemens syngo MultiModality Workplace (syngo MMWP,
VE36A). Volumes-of-Interest (VOIs) of different sizes and
shapes adapted to the various organs/tissues were manu-
ally drawn by combining the information from the CT and
PET acquisitions. In the study group, both examinations in
the same patient were simultaneously evaluated using the
commercial software to align the PET acquisitions and
applying identical VOIs at the same location between the
two studies.
In the study group, a large VOI was allocated on each
side of the mid-line encompassing the BAT activity of
the neck and the periclavicular regions in the consecutive
coronal sections at the first examination. SUVmax of both
VOIs was calculated. The identical evaluation was done at
the second examination.
In the study group, as well as in the control subjects,
SUVmean of the liver was calculated by averaging the
values of VOIs with a volume of 20 to 50 cm3 allocated
Table 1 Mean SUV’s (±SD) of various organs/tissues in 12






Liver SUVmean 2.1 ± 0.2 2.1 ± 0.3 ns
Spleen SUVmean 1.7 ± 0.2 1.7 ± 0.2 ns
Lung SUVmean 0.4 ± 0.1 0.4 ± 0.1 ns
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SUVmean of the spleen was similarly averaged from three
elliptical VOIs with a volume of 4 to 8 cm3 in various
portions of the organ. SUVmean of the lungs was calcu-
lated by averaging the values of parasagittal, ‘flat’ VOIs
with a volume of 25 to 50 cm3 in each lung, covering
both the upper and lower lobes. Blood SUVmean was
assessed by averaging the activity of five VOIs with a vol-
ume of 0.8 to 2 cm3 allocated in different portions of the
lumen of the large mediastinal vessels. As they could not
be discerned from the diffuse mediastinal FDG activity
in most patients, allocation of these VOIs was done
using the CT images. In cases of increased activity of the
vessel wall, this was avoided. Muscular SUVmean was
calculated by averaging the values of elliptical VOIs
allocated in the right and left shoulder muscles (25 to
50 cm3), in both psoas muscles (5 to 10 cm3) and in the
right and left gluteal muscles (25 to 50 cm3), respect-
ively. Bone marrow SUVmean was calculated by averaging
the values of elliptical VOIs with a volume of 2 to 5 cm3
allocated in both iliac crests and spherical VOIs with a
volume of 1 to 1.5 cm3 in each lumbar vertebral body. If
a vertebra was not possible to evaluate because of a
compression or extensive spondylosis, it was excluded.
In a few studies, one or two of the lower dorsal vertebrae
were instead included. SUVmean of the gluteal fat was
assessed by allocating an elliptical VOI with a volume of
5 to 25 cm3. Abdominal SUVmean, mainly representing
intestinal activity, was calculated from a ‘flat’ elliptical
VOI with a volume of 200 to 500 cm3 allocated in the
mid-abdomen avoiding the urinary tracts, female internal
genital organs and any pathological lesion. The cardiac
uptake was assessed by enclosing the left myocardium by
a VOI from which SUVmean and SUVmax were calculated.
SUVmax of the tumour/metastases were identically
calculated at both examinations in the six patients of the
study group showing pathological lesions. In the 2
individuals with 1 or 2 lesions, all were assessed, while
in the 4 individuals with ≥3 lesions, 3 randomly selected
lesions were assessed. In each of these patient, SUVmax
was averaged. The values were thereafter averaged and
the uptake before and after propranolol treatment
compared.Blood SUVmean 1.4 ± 0.2 1.4 ± 0.2 ns
Muscle SUVmean 0.8 ± 0.3 0.7 ± 0.2 ns
Bone marrow
SUVmean
1.8 ± 0.3 1.6 ± 0.4 *
Gluteal fat SUVmean 0.2 ± 0.1 0.2 ± 0.1 ns
Abdomen SUVmean 1.1 ± 0.2 1.1 ± 0.3 ns
Heart SUVmean 3.4 ± 2.6 4.3 ± 3.2 ns
Heart SUVmax 8.1 ± 6.3 10.6 ± 8.4 ns
FDG PET/CT examination was performed before and after pretreatment
with propranolol.
Asterisk denotes 0.01 ≤ p < 0.05; ns, not significant.Propranolol effect on BAT
The BAT activity was normalised in all individuals
between the two examinations at visual evaluation. This
was an inclusion criterion. Mean SUVmax of the VOI
encompassing the brown fat decreased at the right-hand
side of the mid-line from 12.9 ± 7.1 to 1.7 ± 0.4 and on
the left-hand side from 12.6 ± 7.5 to 1.7 ± 0.4, respectively.
1.7 is in the same range as the normal blood activity of the
PET system used [6].Statistical methods
The distribution of the data allowed for the use of the
paired Student’s t test for comparison between the two
examinations of the study group. The Mann–Whitney U
test was applied for comparisons between the study
group and the control subjects. P < 0.05 was considered
statistically significant.
Results
The difference of SUV’s in the study group, i.e. between
examinations in the same patient before and after pre-
treatment with propranolol, was very small. It was re-
stricted to a slightly lower, but significant, bone marrow
uptake after propranolol administration (Table 1).
The difference between the study group and the control
subjects was also small. Also at this comparison, there was
a difference of the bone marrow activity. This was higher
at examination before propranolol pretreatment compared
to the control subjects which showed no difference com-
pared to examination after propranolol pretreatment
(Table 2). In addition, there was a weak but significantly
higher uptake of the spleen in the study group before pro-
pranolol treatment compared to the control subjects.
There were no significant differences between the individ-
uals of the study group after propranolol administration
and the control subjects.
In the six patients of the study group with pathological
lesions, mean SUVmax of these increased from 6.5 ± 1.1 to
6.9 ± 1.1 between the two examinations. The difference
was not statistically significant.
Discussion
Only patients with a BAT uptake being normalised at
the recall examination were studied. No individual with
Table 2 Mean SUV’s (±SD) of various organs/tissues in 12 patients and in 25 control (normal) subjects
Organ/tissue Before propranolol Significance Control subjects Significance After propranolol
Liver SUVmean 2.1 ± 0.2 ns 2.2 ± 0.4 ns 2.1 ± 0.3
Spleen SUVmean 1.7 ± 0.2 * 1.5 ± 0.3 ns 1.7 ± 0.2
Lung SUVmean 0.4 ± 0.1 ns 0.4 ± 0.1 ns 0.4 ± 0.1
Blood SUVmean 1.4 ± 0.2 ns 1.3 ± 0.3 ns 1.4 ± 0.2
Muscle SUVmean 0.8 ± 0.3 ns 0.7 ± 0.2 ns 0.7 ± 0.2
Bone marrow SUVmean 1.8 ± 0.3 * 1.5 ± 0.4 ns 1.6 ± 0.4
Gluteal fat SUVmean 0.2 ± 0.1 ns 0.2 ± 0.1 ns 0.2 ± 0.1
Abdomen SUVmean 1.1 ± 0.2 ns 1.1 ± 0.2 ns 1.1 ± 0.3
Heart SUVmean 3.4 ± 2.6 ns 4.3 ± 1.7 ns 4.3 ± 3.2
Heart SUVmax 8.1 ± 6.3 ns 9.9 ± 4.4 ns 10.6 ± 8.4
FDG PET/CT examination was performed before and after pretreatment with propranolol.
Asterisk denotes 0.01 ≤ p < 0.05; ns, not significant.
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the BAT activity was included. We tried to evaluate as
many organs/tissues as possible. This could not be made
of the brain as it was not included at many examinations.
In addition, and unfortunately, it was not possible of the
urinary tracts. Propranolol reduces the renal plasma flow
and the glomerular filtration rate when given acutely [7].
Consequently, the β-blocker could exert an indirect effect
on the FDG distribution. The renal parenchyma is too
thin to calculate adequate SUVs, and because of normal
variations in the diuresis, analysis of the urinary activity
cannot be relevant.
The main finding of the study is that the difference
between the examinations in the study group is very
small and restricted to a minor difference of the bone
marrow uptake. Surprisingly, and in contrast to our
previous study, the heart uptake of FDG was not
reduced but increased insignificantly after pretreatment
with propranolol [5].
The administration of propranolol enabled the study
but introduces an uncontrolled variable. Outside the
effect on BAT, propranolol exerts pharmacodynamical
effects on various organs/tissues which could interfere
with the findings in study group. In an effort to control
this, the control subjects were included in the study.
Comparing the study group with the control subjects, the
differences were also small. The higher bone marrow up-
take of the study group before propranolol treatment
compared to the control subjects cannot be explained. It
upsets the observed difference of the bone marrow activity
in the study group before and after propranolol adminis-
tration, why this may be a random phenomenon. The
higher uptake of the spleen in the study group before
propranolol treatment compared to the control subjects
can neither be explained and may have the same explan-
ation. Even if the number of studied patients is small, the
restricted effects together with that were no differencesbetween the individuals of the study group after propran-
olol administration and the control subjects strongly indi-
cates that an effect by propranolol can be disregarded.
Conclusions
Along with the increasing availability of usually expensive
drugs for tailored tumour therapy, treatment assessment
constitutes a growing application of FDG/PET. Such lon-
gitudinal comparisons require strictly standardised condi-
tions between the examinations which is difficult to
achieve. The study indicates that in this respect differences
in BAT-uptake between serial examinations can be disre-
garded. This is in contrast to a generally increased FDG
uptake of skeletal muscles where the uptake of normal
tissues, as well as of pathological lesions, is reduced. The
difference may be explained by the much smaller tissue
volume of BAT accumulating the tracer compared to the
volume of the skeletal muscles.
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